We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 863

More clarity for complex biosimilars: Europe approved the first follow-on monoclonal antibodies Canada follows suit

  • Bereskin & Parr LLP
  • -
  • Canada, European Union
  • -
  • March 7 2014

Last year, the European Medicines Agency (EMA) granted marketing authorizations to two biosimilar versions of Johnson & Johnson's rheumatoid

French implementation of the EFPIA Code on disclosure of transfers of value in the light of the French Sunshine Act

  • PDG Avocats
  • -
  • European Union, France
  • -
  • March 19 2014

During the second part of 2011, the French government decided to review the current French Health Product system following the Mediator scandal. Law

European Commission publishes report on external reference pricing for medicinal products

  • Hogan Lovells
  • -
  • European Union
  • -
  • March 18 2014

On 10 March 2014, the European Commission ("Commission") published a report which details the results of an assessment of external reference pricing

Italian Competition Authority opens investigation into two leading pharmaceutical companies

  • Bryan Cave LLP
  • -
  • European Union, Italy
  • -
  • March 14 2014

On 29th January 2014, the Italian Competition Authority ("ICA") opened an in-depth investigation into two leading Italian companies in the

AG’s opinion brings additional plant protection for safeners closer

  • De Brauw Blackstone Westbroek
  • -
  • European Union
  • -
  • March 10 2014

The ECJ ruled in GSK Biologics that an adjuvant that is part of a medical product, which adjuvant influences the therapeutic effects of the active

Methods of medical treatment claims issues in Canada, US and Europe

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, European Union, USA
  • -
  • November 30 2012

In this presentation, Scott Foster and Konrad Sechley address methods of medical treatment claims issues in Canada, US and Europe

Pharmaceutical trade marks case law round up for 2012early 2013

  • Corrs Chambers Westgarth
  • -
  • Australia, European Union, USA
  • -
  • June 6 2013

A brief wrap-up of recent decisions relating to trade marks in the pharma space from the EU, the United States and Australia

Several pharmaceutical companies appeal against Commission’s Lundbeck decision concerning delaying market entry of generic medicines

  • Roschier
  • -
  • European Union
  • -
  • November 13 2013

On 9 November 2013, details were published of appeals brought by Ranbaxy Laboratories Ltd and Ranbaxy (UK) Ltd, Merck KGaAGenerics UK (Generics UK

CJEU confirms the availability of negative term Supplementary Protection Certificates ("SPCs") in Januvia case

  • Hogan Lovells
  • -
  • European Union
  • -
  • December 8 2011

The Court of Justice of the European Union (CJEU) gave its decision in the Januvia case today, 8 December 2011

European Commission proposed overhaul of EU clinical trials legislation

  • Latham & Watkins LLP
  • -
  • European Union
  • -
  • July 30 2012

On July 17, 2012 the European Commission adopted a proposal to reform the existing EU clinical trials regulatory framework